NeuroVia closes $14mm Series A round

15:40 EDT 1 Aug 2017 | Elsevier Business Intelligence

NeuroVia Inc. (small-molecule therapeutics for rare CNS diseases) closed a $14mm Series A round co-led by Novartis Venture Fu...

Original Article: NeuroVia closes $14mm Series A round


More From BioPortfolio on "NeuroVia closes $14mm Series A round"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...